Company Registration No. 14327803 (England and Wales)
Weymouth Pharma Ltd
Unaudited accounts
for the period from 31 August 2022 to 31 August 2023
Weymouth Pharma Ltd
Unaudited accounts
Contents
Weymouth Pharma Ltd
Company Information
for the period from 31 August 2022 to 31 August 2023
Directors
Sunil Varghese Chacko
Moyosoreoluwa Ogunfowoke
Company Number
14327803 (England and Wales)
Registered Office
19 Fuchsia Gardens
Southampton
SO16 6TY
United Kingdom
Weymouth Pharma Ltd
Statement of financial position
as at 31 August 2023
Cash at bank and in hand
30,733
Creditors: amounts falling due within one year
(227,265)
Net current liabilities
(55,049)
Total assets less current liabilities
182,325
Creditors: amounts falling due after more than one year
(181,210)
Called up share capital
100
Profit and loss account
1,015
For the period ending 31 August 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 4 April 2024 and were signed on its behalf by
Sunil Varghese Chacko
Director
Company Registration No. 14327803
Weymouth Pharma Ltd
Notes to the Accounts
for the period from 31 August 2022 to 31 August 2023
Weymouth Pharma Ltd is a private company, limited by shares, registered in England and Wales, registration number 14327803. The registered office is 19 Fuchsia Gardens, Southampton, SO16 6TY, United Kingdom.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have been consistently applied within the same accounts.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts are presented in £ sterling.
Intangible fixed assets (including purchased goodwill and patents) are included at cost less accumulated amortisation.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Computer equipment
20% reduce balance basis
4
Intangible fixed assets
Goodwill
Charge for the period
3,951
Weymouth Pharma Ltd
Notes to the Accounts
for the period from 31 August 2022 to 31 August 2023
5
Tangible fixed assets
Computer equipment
Charge for the period
1,070
Amounts falling due within one year
7
Creditors: amounts falling due within one year
2023
Taxes and social security
1,247
Loans from directors
171,524
8
Creditors: amounts falling due after more than one year
2023
9
Average number of employees
During the period the average number of employees was 4.